# Marimed Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Marimed Inc.). ## Overview MariMed Inc. is a U.S.-based multi-state cannabis operator that develops, owns, and manages licensed cultivation, production, and dispensary operations for medicinal and adult-use cannabis. The company also builds consumer brands and licenses those brands in select domestic markets, combining retail, wholesale, and managed-services revenue streams. ## Products & services • Cannabis flower, concentrates, edibles, and precision-dosed products • Retail dispensary sales of medicinal and adult-use cannabis • Wholesale distribution of MariMed-branded products • Brand licensing to wholesalers and regulated dispensaries • Real estate rentals and cannabis facility management services • Supply procurement and operational oversight for licensed clients - **Retail cannabis sales** (45%) — Direct sales of cannabis and cannabis-infused products through company dispensaries. - **Wholesale branded products** (35%) — Sales of MariMed-owned brands to third-party dispensaries and wholesalers. - **Managed services and licensing** (10%) — Management fees, licensing fees, and operational support for cannabis license holders. - **Real estate and procurement services** (10%) — Rental income and supply procurement fees tied to cannabis facilities and clients. - Cannabis flower, concentrates, edibles, and precision-dosed products - Retail dispensary sales of medicinal and adult-use cannabis - Wholesale distribution of MariMed-branded products - Brand licensing to wholesalers and regulated dispensaries - Real estate rentals and cannabis facility management services - Supply procurement and operational oversight for licensed clients ## Customers MariMed sells primarily to cannabis consumers through its retail dispensaries and to wholesale buyers such as regulated dispensaries and other licensed operators. It also serves cannabis license holders and facility owners that use its management, procurement, rental, and brand-licensing services. Demand is driven by state-regulated access to cannabis products, brand recognition, product quality, and convenience at retail. - **Retail dispensary consumers** (primary) — Patients and adult-use customers buying cannabis flower, edibles, concentrates, and other products at MariMed stores. - **Wholesale dispensaries and distributors** (primary) — Licensed retailers and wholesalers purchasing MariMed brands such as Betty's Eddies for resale. - **Managed cannabis operators** (secondary) — Licensed operators that pay for day-to-day management, compliance, and operational oversight. - **Real estate and facility clients** (secondary) — Cannabis-licensed clients leasing property or using MariMed-managed facilities and services. - Retail cannabis consumers seeking medicinal or adult-use products - Wholesale dispensaries buying MariMed-branded products for resale - Licensed cannabis operators using management and oversight services - Cannabis license holders leasing facilities or real estate from MariMed - Third parties buying procurement and supply-chain support services ## Geography MariMed operates in multiple U.S. states and is headquartered in Norwood, Massachusetts. Its footprint expanded through acquisitions in Delaware, Illinois, and Maryland, and it also manages a cultivation facility in Pennsylvania under a services agreement. Because cannabis is regulated at the state level, each operating state has its own licensing, compliance, and market-access profile. - Headquartered in Norwood, Massachusetts - Multi-state U.S. cannabis operations across retail and wholesale channels - Delaware expanded through the First State Compassion Center acquisition - Illinois and Maryland added through 2024 dispensary acquisitions - Pennsylvania management services create an additional operating foothold ## Strategy MariMed is focused on growing branded product revenue by improving cultivation, processing, innovation, and distribution across existing and new markets. It is also expanding retail revenue through better store execution, higher transaction counts, and selective dispensary growth via licenses and acquisitions. The company is using its retail footprint and wholesale relationships together to strengthen brand awareness and market share. - **Expand branded product revenue** (medium-term) — Branded products can scale across retail and wholesale channels and improve market share. - **Increase retail store revenue** (short-term) — Company-owned stores provide direct consumer access, higher transaction frequency, and brand feedback. - **Use managed services and licensing to extend reach** (medium-term) — These arrangements let MariMed monetize its operating expertise without relying only on owned stores. - Strengthen cultivation and processing to improve product consistency - Launch new products and formulations tied to consumer preferences - Broaden distribution in existing markets to increase brand visibility - Expand into new states through licenses, acquisitions, and partners - Drive higher retail transactions through better customer experience - Grow dispensary footprint where regulations and acquisitions allow ## Risks MariMed operates in an industry where cannabis remains illegal under U.S. federal law, so state-by-state licensing and compliance are central to the business model. Growth also depends on acquisitions, integration, and maintaining low-cost, reliable production, while retail and wholesale demand can shift quickly if competitors offer better or cheaper products. The company also faces listing, cybersecurity, credit, and impairment risks that can affect liquidity, operations, and reported earnings. - **Federal illegality of cannabis in the United States** [critical] — The company operates under state law while cannabis remains a Schedule I substance federally, creating legal and regulatory uncertainty. - **State licensing and regulatory compliance** [high] — Each market requires state and local approvals, and noncompliance could suspend or limit operations. - **Competitive pricing and product substitution** [high] — Competitors may offer more effective, easier-to-buy, or cheaper products, reducing MariMed sales and margins. - **Acquisition and integration risk** [medium] — Growth has relied on acquisitions, which can bring contingent liabilities, debt, and goodwill impairment risk. - **Cybersecurity and data breach risk** [medium] — Operational systems and confidential data could be disrupted or compromised by cyber incidents. - **OTCQX listing compliance** [medium] — Failure to meet continued listing standards could reduce liquidity and market value of the stock. - Federal illegality of cannabis creates legal and banking constraints - State licensing and compliance failures could interrupt operations - Competition from MSOs and single-state operators can pressure pricing - Acquisition integration may create debt, liabilities, or goodwill impairment - Cyberattacks could disrupt operations or expose confidential data - OTCQX listing compliance matters for liquidity and market access ## Accounting MariMed’s most important accounting judgments center on revenue recognition across retail, wholesale, licensing, rental, and management-fee streams, each of which may be recognized at different points in time. The company also relies heavily on estimates for inventory valuation, credit losses, depreciation lives, business combinations, contingencies, stock-based compensation, and income taxes, all of which can materially affect reported results. Because cannabis operations are capital intensive and acquisition-driven, impairment and purchase accounting judgments are especially important for investors. - **Revenue recognition by stream** — Affects timing and comparability of revenue across quarters - **Inventory valuation** — Can affect gross margin and write-downs - **Business combinations and goodwill** — Can create non-cash charges that reduce earnings - **Accounts receivable reserves** — Can affect operating income and cash conversion - **Stock-based compensation and tax estimates** — Can materially change reported net income - Revenue recognition differs across product sales, licensing, rentals, and management fees - Retail and wholesale sales are recognized when products are delivered or sold at POS - Inventory valuation is judgmental in a regulated, perishable product business - Acquisition accounting and goodwill impairment can materially affect earnings - Credit loss reserves matter because the company extends payment terms to clients - Stock-based compensation and tax estimates can move reported profit --- *Last updated: 2026-04-28T20:24:11.338578+00:00*